Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or

Han, Lili; Husaiyin, Sulaiya; Zhao, Fanghui; Rezhake, Remila; Niyazi, M.

doi:10.7754/clin.lab.2018.180138

Cited by 6 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, this results in overexpression of the two oncogenes which become useful in evaluating risk of cervical carcinogenesis. This consensus is supported by studies included in our review showing that HPV E6/E7 mRNA assays have diagnostic relevance for CIN2+ with sensitivity, specificity, PPV, NPV, and AUC ranges of 65-100%, 42.7-90.2%, 10-85.9%, 66.7-100%, and 0.59-0.80, respectively, [13,29,32,33]. However, due to the heterogeneity of participants in the included studies, the results of HPV E6/E7 mRNA test performance have limited generalizability.…”

Section: Discussionsupporting

confidence: 63%

“…The diagnostic performance of each of the assays as compared with histologically confirmed high-grade cervical intraepithelial neoplasia (CIN2+) as an endpoint was as follows; 1) HPV E6/E7 mRNA test performance varied considerably depending on the diagnostic method used as shown in Table 1. Eight of the studies included recorded a sensitivity, specificity, PPV, NPV, and Area Under Receiver Operating Characteristic Curve (AUC) ranges of 65-100%, 42.7-90.2%, 10-85.9%, 66.7-100%, and 0.59-0.80, respectively, using liquid based cytology (LBC) samples majorly on QuantiVirus®HPV platform [13,29,[32][33][34][35][36][37]. 2).…”

Section: Diagnostic Performance Of the Listed Assays To Detect Cin2+mentioning

confidence: 99%

See 1 more Smart Citation

Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review

Onyango

Ogonda

Guyah

et al. 2020

Infect Agents Cancer

View full text Add to dashboard Cite

Background Cervical cancer screening is slowly transitioning from Pappanicolaou cytologic screening to primary Visual Inspection with Acetic Acid (VIA) or HPV testing as an effort to enhance early detection and treatment. However, an effective triage tests needed to decide who among the VIA or HPV positive women should receive further diagnostic evaluation to avoid unnecessary colposcopy referrals is still lacking. Evidence from experimental studies have shown potential usefulness of Squamous Cell Carcinoma Antigen (SCC Ag), Macrophage Colony Stimulating Factor (M-CSF), Vascular Endothelial Growth Factor (VEGF), MicroRNA, p16INKa / ki-67, HPV E6/E7/mRNA, and DNA methylation biomarkers in detecting premalignant cervical neoplasia. Given the variation in performance, and scanty review studies in this field, this systematic review described the diagnostic performance of some selected assays to detect high-grade cervical intraepithelial neoplasia (CIN2+) with histology as gold standard. Methods We systematically searched articles published in English between 2012 and 2020 using key words from PubMed/Medline and SCOPUS with two reviewers assessing study eligibility, and risk of bias. We performed a descriptive presentation of the performance of each of the selected assays for the detection of CIN2 + . Results Out of 298 citations retrieved, 58 articles were included. Participants with cervical histology yielded CIN2+ proportion range of 13.7–88.4%. The diagnostic performance of the assays to detect CIN2+ was; 1) SCC-Ag: range sensitivity of 78.6–81.2%, specificity 74–100%. 2) M-CSF: sensitivity of 68–87.7%, specificity 64.7–94% 3) VEGF: sensitivity of 56–83.5%, specificity 74.6–96%. 4) MicroRNA: sensitivity of 52.9–67.3%, specificity 76.4–94.4%. 5) p16INKa / ki-67: sensitivity of 50–100%, specificity 39–90.4%. 6) HPV E6/E7/mRNA: sensitivity of 65–100%, specificity 42.7–90.2%, and 7) DNA methylation: sensitivity of 59.7–92.9%, specificity 67–98%. Conclusion Overall, the reported test performance and the receiving operating characteristics curves implies that implementation of p16ink4a/ki-67 assay as a triage for HPV positive women to be used at one visit with subsequent cryotherapy treatment is feasible. For the rest of assays, more robust clinical translation studies with larger consecutive cohorts of women participants is recommended.

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Diagnostic Performance Of the Listed Assays To Detect Cin2+mentioning

confidence: 99%

Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review

Onyango

Ogonda

Guyah

et al. 2020

Infect Agents Cancer

View full text Add to dashboard Cite

show abstract

“…However, our result was lower than that of samples with abnormal cytological outcomes collected at the Affiliated Hospital of Xinjiang Medical University [ 25 ]. In addition, this study showed that the cervical cancer detection rate was 1.48%, which was higher than that reported by Husaiyin et al (who conducted cervical cancer examinations in Pishan County) [ 26 ] and by Han et al (whose study was conducted in Urumqi) [ 27 ]. Different sample sources could account for these inconsistencies.…”

Section: Discussioncontrasting

confidence: 66%

ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

The timely detection of precancerous lesions and early intervention can greatly reduce cervical cancer occurrence. The current study aimed to assess the diagnostic value and accuracy of different methods of cervical lesion screening. A total of 1622 females who visited the Outpatient Department of Xinjiang Uyghur Autonomous Region People’s Hospital between January and December 2018 were consecutively enrolled. All participants underwent separate high-risk human papilloma virus (HR-HPV) DNA detection, ThinPrep cytology testing (TCT) and colposcopic biopsy. Their medical records were retrospectively analyzed. While considering biopsy outcomes as the gold standard, the diagnostic values of TCT, HR-HPV testing, and TCT+HR-HPV testing for cervical cancer screening were compared. The sensitivity, specificity and Youden index of each method were calculated. Among the different methods, TCT+HR-HPV testing had the highest sensitivity (89.8%), followed by TCT (79.9%) and HR-HPV testing (49.2%). The combined method also had the highest Youden value, and its screening outcomes exhibited the highest consistency with those of biopsy. In addition, the combined method had the largest area under the receiver operating characteristic (ROC) curve, which was 0.673 (0.647, 0.699), compared with any other screening method. Compared with TCT or HR-HPV testing alone, TCT+HR-HPV testing serves as a better screening method for cervical cancer and precancerous lesions.

show abstract

“…Our review result is in line with this argument. On top of this, the reported AU-ROC curve by six of the articles [51,[58][59][60][61][62] Burger et al [63] review on HPV mRNA tests for the detection of cervical intraepithelial neoplasia reported sensitivities between 41 and 86% and 90-95% for the PreTect Proofer/Easy Q and APTIMA assay, respectively. Similarly, the reported specificities vary from 63 to 97% and 42-61% for the PreTect Proofer/Easy Q and APTIMA assay, respectively.…”

Section: Discussionmentioning

confidence: 99%

HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): A systematic review

Derbie

Mekonnen

Woldeamanuel

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Genital infection with certain types of Human papillomavirus (HPV) is a major cause of cervical cancer globally. For early detection of premalignant dysplasia, evidences are coming out on the usefulness of HPV E6/E7 mRNA test as a potential tool compared with cytology and HPV DNA testing. Taking into account shortage of compiled data on this field, the aim of this systematic review was to describe the latest diagnostic performance of HPV E6/E7 mRNA testing to detect high grade cervical lesions (CIN2+) where by histology as was taken as a ‘gold standard’. Methods: Articles published in English were systematically searched using key words from PubMed/Medline and SCOPUS. In addition, Google Scholar and the Google database were searched manually for grey literature. Two reviewers independently assessed study eligibility, risk of bias and extracted the data. We performed a descriptive presentation of the performance of E6/E7 mRNA testings (interims of sensitivity, specificity, negative and positive predictive values) for the detection of CIN2+. Results: Out of 231 applicable citations, we have included 29 articles with a total of 23,576 study participants (age range, 15-84) who had different cervical pathologies. Among the participants who had cervical histology, the proportion of CIN2+ was between 10.6% and 90.6%. Using histology as a gold standard, 11 studies evaluated the PreTect HPV Proofer, 7 studies evaluated the APTIMA HPV assay (Gen-Probe) and 6 studies evaluated the Quantivirus® HPV assay. The diagnostic performance of those three most common mRNA testing tools to detect CIN2+ was; 1) PreTect Proofer; median sensitivity 83%, median specificity 73%, median PPV 70 and median NPV 88.9%. 2) APTIMA assay; median sensitivity 91.4%, median specificity 46.2%, median PPV 34.3% and median NPV 96.3%. 3) Quantivirus®: median sensitivity 86.1%, median specificity 54.6%, median PPV 54.3%, median NPV 89.3%. Further, the area under the receiver operating characteristics (AU-ROC) curve varied between 63.8% and 90.9%. Conclusions: The reported diagnostic accuracy implies that mRNA tests possess diagnostic relevance to detect CIN2+ and could potentially be considered in areas where there is no histology facility. Further studies including its cost should be considered.

show abstract

Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or

Cited by 6 publications

References 24 publications

Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review

Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review

ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients

HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): A systematic review

Contact Info

Product

Resources

About